Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer

December 11th 2024, 6:35pm

San Antonio Breast Cancer Symposium

Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.

Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

December 11th 2024, 6:30pm

San Antonio Breast Cancer Symposium

Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

December 11th 2024, 6:02pm

ASH Annual Meeting and Exposition

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

Potential Biomarkers Positively Prognosticate Outcomes With Pembrolizumab Plus Chemo in High-Risk TNBC

December 11th 2024, 5:54pm

San Antonio Breast Cancer Symposium

Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

December 11th 2024, 4:15pm

ASH Annual Meeting and Exposition

Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.

Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer

December 11th 2024, 1:00am

San Antonio Breast Cancer Symposium

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET

December 11th 2024, 12:26am

ASH Annual Meeting and Exposition

NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma

December 10th 2024, 10:30pm

ASH Annual Meeting and Exposition

Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma

December 10th 2024, 10:21pm

ASH Annual Meeting and Exposition

Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

December 10th 2024, 10:20pm

ASH Annual Meeting and Exposition

Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR

December 10th 2024, 9:46pm

ASH Annual Meeting and Exposition

Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.

Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

December 10th 2024, 9:42pm

ASH Annual Meeting and Exposition

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL

December 10th 2024, 9:42pm

ASH Annual Meeting and Exposition

First-line pirtobrutinib plus venetoclax and obinutuzumab generated high uMRD6 remission rates among patients with chronic lymphocytic leukemia.

Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML

December 10th 2024, 9:37pm

ASH Annual Meeting and Exposition

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Dr Rau on Treatment With Blinatumomab and Chemo in Newly Diagnosed Pediatric B-ALL

December 10th 2024, 9:08pm

ASH Annual Meeting and Exposition

Rachel E. Rau, MD, discusses findings that show blinatumomab plus chemotherapy improves DFS in newly diagnosed B-ALL.

Dr Fenske on ASCT Outcomes in MCL After First MRD-Negative CR

December 10th 2024, 8:40pm

ASH Annual Meeting and Exposition

Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL

December 10th 2024, 8:33pm

ASH Annual Meeting and Exposition

Axi-cel sustained long-term efficacy in relapsed/refractory follicular lymphoma and marginal zone lymphoma.

Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM

December 10th 2024, 8:16pm

ASH Annual Meeting and Exposition

The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

December 10th 2024, 7:44pm

ASH Annual Meeting and Exposition

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma

December 10th 2024, 7:30pm

ASH Annual Meeting and Exposition

The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.

NEXT PAGE
PREVIOUS PAGE